Acadian Asset Management
TRIB

Acadian Asset Management’s Trinity Biotech TRIB Stock Holding History

Acadian Asset Management’s Portfolio TRIB Stock Details TRIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-41,839
Closed -$46K – 2166
2024
Q3 		$46K Sell
41,839
-30,271
-42% -$68.2K ﹤0.01% 1819
2024
Q2 		$149K Sell
72,110
-44,166
-38% -$85.7K ﹤0.01% 1482
2024
Q1 		$237K Sell
116,276
-20,700
-15% -$48.5K ﹤0.01% 1161
2023
Q4 		$292K Sell
136,976
-7,731
-5% -$18.5K ﹤0.01% 1153
2023
Q3 		$526K Sell
144,707
-884
-0.6% -$3.62K ﹤0.01% 993
2023
Q2 		$701K Sell
145,591
-2,920
-2% -$14.1K ﹤0.01% 973
2023
Q1 		$696K Sell
148,511
-1,731
-1% -$8.92K ﹤0.01% 971
2022
Q4 		$741K Sell
150,242
-1,800
-1% -$10.9K ﹤0.01% 925
2022
Q3 		$811K Hold
152,042
– – ﹤0.01% 854
2022
Q2 		$931K Sell
152,042
-11,050
-7% -$67.5K ﹤0.01% 837
2022
Q1 		$862K Sell
163,092
-5,613
-3% -$32.3K ﹤0.01% 865
2021
Q4 		$1.2M Sell
168,705
-2,369
-1% -$22.4K ﹤0.01% 788
2021
Q3 		$1.84M Buy
171,074
+3,434
+2% +$40.3K 0.01% 703
2021
Q2 		$2.46M Buy
167,640
+16,981
+11% +$283K 0.01% 650
2021
Q1 		$2.83M Buy
150,659
+25,771
+21% +$620K 0.01% 635
2020
Q4 		$2.38M Buy
124,888
+21,865
+21% +$362K 0.01% 712
2020
Q3 		$1.04M Buy
103,023
+68,818
+201% +$796K ﹤0.01% 901
2020
Q2 		$373K Buy
+34,205
New +$261K ﹤0.01% 1295
2018
Q4 		– Sell
-1,163
Closed -$23K – 1836
2018
Q3 		$23K Hold
1,163
– – ﹤0.01% 1498
2018
Q2 		$29K Buy
+1,163
New +$28K ﹤0.01% 1493
2017
Q2 		– Sell
-9,582
Closed -$286K – 1590
2017
Q1 		$286K Buy
+9,582
New +$300K ﹤0.01% 986
2014
Q4 		– Sell
-1,533
Closed -$140K – 1329
2014
Q3 		$140K Sell
1,533
-9,250
-86% -$1M ﹤0.01% 802
2014
Q2 		$1.24M Sell
10,783
-15,796
-59% -$1.87M 0.01% 567
2014
Q1 		$3.22M Sell
26,579
-26,716
-50% -$3.5M 0.02% 397
2013
Q4 		$6.7M Sell
53,295
-24,274
-31% -$2.91M 0.04% 302
2013
Q3 		$8.44M Sell
77,569
-13,870
-15% -$1.35M 0.05% 250
2013
Q2 		$7.7M Buy
+91,439
New +$7.58M 0.05% 240

Other funds holding TRIB

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HAIM
Hunter Associates Investment Management Pittsburgh, Pennsylvania $756M AUM 19.99% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
WCM
Whitefort Capital Management New York $339M AUM 52.48% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
MAWA
Moss Adams Wealth Advisors Seattle, Washington $1.37B AUM 19.97% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return
BCM
Becker Capital Management Portland, Oregon $3.4B AUM 24.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

Acadian Asset Management's TRIB Position: Q4 2024 in Review

Acadian Asset Management sold out of Trinity Biotech (TRIB) in Q4 2024, closing a stake of 41,839 shares — an estimated $46K sold.

Acadian Asset Management first reported a position in TRIB in Q2 2013 and held it in 27 quarters. The position peaked at $8.44M in Q3 2013. 23 funds tracked by Wall St. Rank hold TRIB as of Q4 2024.

  • Acadian Asset Management reported no remaining Trinity Biotech position as of Q4 2024 after selling out during the quarter.
  • Acadian Asset Management sold 41,839 Trinity Biotech shares in Q4 2024, an estimated $46K.
  • Acadian Asset Management first reported a position in Trinity Biotech in Q2 2013 and held it in 27 quarters.
  • Acadian Asset Management's Trinity Biotech position peaked at $8.44M in Q3 2013.
  • 23 funds tracked by Wall St. Rank held Trinity Biotech as of Q4 2024.

Based on Acadian Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.